Consensus sets EUR 51.00 target for Dermapharm stock

Published on 10/15/2026 at 19:50 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue reached EUR 285.20 million in the second quarter. Dermapharm stock costs EUR 38.15 on October 15, 2026, unchanged versus the Xetra close.

Analyst target and earnings

A four-analyst consensus set a 12-month target of EUR 51.00 on October 8, 2026.
Second-quarter 2026 revenue reached EUR 285.20 million and earnings per share reached EUR 0.47.
Dermapharm stock costs EUR 38.15 at Lang & Schwarz on October 15, 2026 at 7:41 p.m. CEST, unchanged versus the Xetra close of October 15, 2026.
The next earnings report is scheduled for November 12, 2026.

Architektur-Render moderner Pharmakonzern-Hauptsitz, Glas und Beton, Abendlicht — Dermapharm Holding DE000A2GS5D8 Firmenzentrale als modernes Architektur-Render mit Glasfassade im warmen Abendlicht und Grünanlage, Illustration mit AI erstellt.

According to Investing.com on October 8, 2026, the four-analyst 12-month consensus target was EUR 51.00, 33.68 percent above the Lang & Schwarz price quoted on October 15, 2026 at 7:41 p.m. CEST. At Lang & Schwarz, Dermapharm stock was trading at EUR 38.15 on October 15, 2026 at 7:41 p.m. CEST, unchanged versus the Xetra close.

Second-quarter revenue reaches EUR 285.20 million

Makkler lists Dermapharm's second-quarter 2026 report date as August 25, 2026, with revenue of EUR 285.20 million and earnings per share of EUR 0.47. The revenue figure gives the valuation discussion a current operating anchor, while the quarterly result remains the latest reported period in the available financial record.

Price stays 26.49 percent below high

The EUR 38.15 quote stood 26.49 percent below the 52-week high of EUR 51.90 and 17.75 percent above the 52-week low of EUR 32.40, with both figures measured as of October 15, 2026 at 7:35 p.m. CEST. Trading volume was 27,513 shares against an average volume of 32,701 shares on the same date. The bid was EUR 37.70 and the ask EUR 38.60 at Lang & Schwarz on October 15, 2026 at 7:41 p.m. CEST.

Valuation and November 12 date

Dermapharm's market capitalization was EUR 1.9 billion as of October 15, 2026, while its price-to-earnings ratio was 13.77. The next earnings report is scheduled for November 12, 2026, according to Makkler.

Comparison with peers

Dermapharm: unchanged, P/E 13.77, market capitalization EUR 1.9 billion
Bayer (Xetra, EUR): minus 1.46 percent, P/E minus 25.23, market capitalization EUR 43.6 billion
Novartis (SIX, CHF): plus 2.64 percent, P/E 23.20, market capitalization CHF 239.3 billion

Price and investor perspective

Dermapharm's unchanged euro quote leaves the analyst consensus target as the clearest numerical comparison for the stock. The distance to the 52-week high is wider than the 17.75 percent cushion above the low, while the next earnings date gives investors a defined calendar point for reassessing the operating picture. Eulerpool identifies Dermapharm Holding as DMP.DE on Xetra and assigns ISIN DE000A2GS5D8 in its company profile.

Dermapharm stock was trading at EUR 38.15 at Lang & Schwarz on October 15, 2026 at 7:41 p.m. CEST, unchanged versus the Xetra close of October 15, 2026 at EUR 38.15. The further course of trading is shown by the continuously updated real-time quote of Dermapharm stock.